Loading...
•
Sep 30, 2021
Zai Lab Q3 2021 Earnings Report
Zai Lab entered into a collaboration and license agreement with Blueprint Medicines for BLU-945 and BLU-701 in Greater China.
Key Takeaways
Zai Lab and Blueprint Medicines announced an exclusive collaboration and license agreement for the development and commercialization of BLU-945 and BLU-701 for the treatment of patients with epidermal growth factor receptor (EGFR) -driven non-small cell lung cancer (NSCLC) in Greater China.
Zai Lab obtains exclusive rights to develop and commercialize BLU-945 and BLU-701 in Greater China.
Collaboration accelerates and expands global development of Blueprint Medicines’ next- generation EGFR inhibitors with plans to bring clinical trials of BLU-945 and BLU-701 to Greater China.
Blueprint Medicines will receive $25 million upfront payment.
Blueprint Medicines is eligible to receive up to $590 million in potential future milestone payments, and royalties.